IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Boeing Acquisition of Spirit AeroSystems Could Close Soon Amid Ongoing Conditions 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
Boeing Executive Says Trump’s Equity Stake Plan Won’t Target Major Defense Contractors 
Lockheed Martin Secures $1.14 Billion Contract Boost for F-35 Production 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Spirit Airlines Reverses Pilot Furlough Plans Amid Updated Staffing Outlook 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Visa to Move European Headquarters to London’s Canary Wharf 
U.S.-EU Tensions Rise After $140 Million Fine on Elon Musk’s X Platform 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Allegiant Air Faces Union Block in Bid for Foreign Pilots’ Green Cards Amid Staffing Challenges 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
CAMBRIDGE, Mass., Feb. 09, 2017 -- Cellaria, LLC, a scientific innovator that develops revolutionary new patient-specific cancer models for challenging tumors, today announced the formation of a strategic partnership with AMS Biotechnology (AMSBIO). As part of the agreement, AMSBIO will distribute, market and sell Cellaria cell models and culture media throughout Europe. The partnership enables Cellaria to better meet growing demand for its products outside the US.
Cellaria's unique patient-specific cell models and cell culture media products expand the current offering AMSBIO has for physiologically relevant cell culture products for drug discovery and other life science applications. Late in 2016, Cellaria announced the availability of new models for High Grade Serous and Endometriod Ovarian Cancer and an ER-positive breast model.
AMSBIO is a premier provider of quality life science research reagents and services helping customers develop innovative methods, processes, products and medicines. As a leading provider of scaffolds, matrices, kits and proteins for growing and screening spheroids and organoids, AMSBIO has contributed to the acceleration of discovery programs in medical research.
Alex Sim, managing director at AMSBIO said, "The new partnership with Cellaria expands our existing portfolio by introducing patient-derived cancer models; allowing customers to conduct research and drug discovery initiatives to advance precision medicine.”
"The unique value of our patient-specific cell models makes AMSBIO an ideal partner for Cellaria," said David Deems, chief executive officer at Cellaria. "Our products will expand the AMSBIO cancer product portfolio, and their technical expertise will enable them to support Cellaria's customers throughout Europe."
About Cellaria
Cellaria creates breakthrough oncology models that reflect the unique nature and complexity of a tumor. Using these informative models, cancer researchers are better able to select promising compounds and work towards personalized approaches that would enable physicians to identify the most effective treatment for each patient's needs. Cellaria's innovative products help lead the research community to more personalized therapeutics, revolutionizing and accelerating the search for a cancer cure. For more information, visit www.cellariabio.com or to learn more about our cell models.
Contact: Tim Walsh for Cellaria Bio 617.512.1641 [email protected]
